The goal of the Clinical Research Support Services Core is to create a shared facility to encourage clinical research at the UCSF Cancer Center. Specific objectives are to; To foster investigator initiated clinical trials through assistance in protocol development, protocol writing, dissemination and distribution of protocols, and provision of data management support; To have an infrastructure to provide compliance with federal guidelines for the conduct of clinical studies and for the appropriate distribution of investigational drugs; To facilitate the recording and reporting of adverse events related to clinical trials and; To create an education and training program for research associates, Cancer Center members and physicians to encourage and promote compliance with clinical trials regulations and requirements including patient eligibility data submission and appropriate follow-up. The Cancer Center Support Services Core serves four campuses and multiple programs located throughout the Cancer Center. The principal support personnel are currently located in space at the Parnassus campus but will be relocated to dedicated Cancer Center space on the Mount Zion campus. Some data managers and nurses will remain in Departmental or Medical space near the main clinical sites, including the San Francisco Veterans Administration Medical Center, San Francisco General Hospital, and the in-patient and out-patient facilities at Mt. Zion and Parnassus.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-04
Application #
6694332
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-09-27
Project End
2007-01-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:

Showing the most recent 10 out of 192 publications